7/26/2022 5:03:00 PM
Teva Loss/share $0.21 Vs. Profit $0.19 Year Ago
7/12/2022 10:33:36 AM
Teva Reaches Agreement With San Francisco To Settle Opioid-Related Claims
7/1/2022 8:43:45 AM
Teva Appoints Eric Hughes As EVP, Global R&D And Chief Medical
Office
6/9/2022 7:47:59 AM
Teva To Present Latest Data On AJOVY Injection At 2022 American Headache Society Annual Meeting
5/25/2022 9:40:52 AM
Teva Reaches Agreement With West Virginia To Settle Opioid-Related
Claims
5/23/2022 8:05:33 AM
Teva : Analysis Finds AUSTEDO Provided Improvements In TD-related Movements In Postmenopausal Women
5/17/2022 9:13:55 AM
United Kingdom Grants License For Teva's Ophthalmology Biosimilar
Ongavia
5/17/2022 7:50:41 AM
Teva Says New Findings Shows Potential Of ProAir Digihaler
Inhalation Powder To Address Asthma Treatment Challenges
5/3/2022 7:16:21 AM
Teva Pharmaceutical Industries Limited (TEVA) Has Lowered Its FY22 Revenue Estimate To $15.4 - $16.0 Bln From $15.6 - $16.2 Bln